Sung-Bae Kim

Sung-Bae Kim, S. Ahn, G. Gong, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Oncologic Safety of Nipple-Sparing Mastectomy in Patients with Breast Cancer and Tumor-to-Nipple Distance ≤ 1 cm: A Matched Cohort Study

Sung-Bae Kim, S. Ahn, G. Gong, 2021, Annals of Surgical Oncology.

Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer.

Sung-Bae Kim, S. Ahn, G. Gong, 2019, JAMA surgery.

Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

Sung-Bae Kim, Y. Im, S. Im, 2009, Breast Cancer Research and Treatment.

The Recurrence Rate, Risk Factors and Recurrence Patterns after Surgery in 3700 Patients with Operable Breast Cancer

Sung-Bae Kim, S. Ahn, S. Yun, 2006 .

Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients.

Sung-Bae Kim, H. Lee, K. Jung, 2016, Breast.

The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.

Sung-Bae Kim, Y. Shim, Y. Im, 2021, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma

Sung-Bae Kim, Y. Bang, B. Cho, 2015, Cancer.

Randomized phase II/III trial of active immunotherapy with OPT-822/OPT-821 in patients with metastatic breast cancer.

Chiun-Sheng Huang, Ming-Feng Hou, Chi-Huey Wong, 2016 .

Polytetrafluoroethylene-covered retrievable expandable nitinol stents for malignant esophageal obstructions: factors influencing the outcome of 270 patients.

Sung-Bae Kim, Jung-Hoon Park, Ho-Young Song, 2012, AJR. American journal of roentgenology.

The Association between Herpes Zoster and Increased Cancer Risk: A Nationwide Population-Based Matched Control Study

Sung-Bae Kim, J. Leem, J. Sim, 2021, Current oncology.

Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II

Sung-Bae Kim, Zhen-zhou Shen, T. Chao, 2015, Journal of breast cancer.

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)

Sung-Bae Kim, Yeon-Hee Park, Y. Im, 2019, Cancer communications.

Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer

Sung-Bae Kim, S. Ahn, G. Gong, 2021, Frontiers in Oncology.

Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer

Sung-Bae Kim, D. Nieboer, J. Ajani, 2021, Annals of surgery.

Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.

Sang‐wook Lee, Sung-Bae Kim, Jong Hoon Kim, 2011, International journal of radiation oncology, biology, physics.

Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.

Kyung-Ja Cho, Sung-Bae Kim, Ho-Young Song, 2009, International journal of radiation oncology, biology, physics.

Patients with ERCC1-Negative Locally Advanced Esophageal Cancers May Benefit from Preoperative Chemoradiotherapy

Kyung-Ja Cho, Sung-Bae Kim, Ho-Young Song, 2008, Clinical Cancer Research.

Treatment outcome and recursive partitioning analysis-based prognostic factors in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy.

Kyung-Ja Cho, Sung-Bae Kim, Ho-Young Song, 2008, International journal of radiation oncology, biology, physics.

ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.

Kyung-Ja Cho, Sung-Bae Kim, Ho-Young Song, 2008, European journal of cancer.

Results of Definitive Chemoradiotherapy for Unresectable Esophageal Cancer.

Sang‐wook Lee, Sung-Bae Kim, G. Lee, 2008 .

Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.

Soo Young Kim, Kyung-Ja Cho, Sung-Bae Kim, 2007, European journal of cancer.

Efficacy of Neoadjuvant Chemoradiotherapy in Resectable Esophageal Squamous Cell Carcinoma

Sung-Bae Kim, Ho-Young Song, Hwoong-Yong Jung, 2003, Acta oncologica.

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2‐negative metastatic breast cancer

Sung-Bae Kim, K. Jung, Jin-Hee Ahn, 2021, International journal of cancer.

HER2+ breast cancer treatment and cardiotoxicity: monitoring and management

Sung-Bae Kim, G. Jerusalem, P. Lancellotti, 2019, Breast Cancer Research and Treatment.

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer

Hee Jung Shin, Sung-Bae Kim, S. Ahn, 2021, Scientific Reports.

Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)

Sung-Bae Kim, Sin-Ho Jung, J. Ahn, 2015, Breast Cancer Research and Treatment.

PR99 QUALITY OF LIFE (QOL) IN METASTATIC BREAST CANCER PATIENTS WITH MAINTENANCE PACLITAXEL PLUS GEMCITABINE (PG) CHEMOTHERAPY: RESULTS FROM PHASE III, MULTICENTER, RANDOMIZED TRIAL OF MAINTENANCE CHEMOTHERAPY VERSUS OBSERVATION (KCSG-BR07-02)

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2013 .

Oncologic Outcomes of Nipple-sparing Mastectomy and Immediate Reconstruction After Neoadjuvant Chemotherapy for Breast Cancer

Sung-Bae Kim, S. Ahn, B. Son, 2020, Annals of surgery.

A Propensity Score-matched Analysis of Long-term Oncologic Outcomes After Nipple-sparing Versus Conventional Mastectomy for Locally Advanced Breast Cancer.

Sung-Bae Kim, S. Ahn, G. Gong, 2020, Annals of surgery.

Long-term Oncologic Outcomes of Immediate Breast Reconstruction vs Conventional Mastectomy Alone for Breast Cancer in the Setting of Neoadjuvant Chemotherapy.

Sung-Bae Kim, S. Ahn, G. Gong, 2020, JAMA surgery.

Clinical implications of endoscopic ultrasonography non-traversability in patients with locoregional esophageal cancer receiving multimodality therapy

Sung-Bae Kim, G. Lee, Jong Hoon Kim, 2016, The Korean journal of internal medicine.

Synchronous second primary cancers in patients with squamous esophageal cancer: clinical features and survival outcome

Kyung-Ja Cho, Sung-Bae Kim, G. Lee, 2016, The Korean journal of internal medicine.

Pretreatment quality of life as a prognostic factor for early survival and functional outcomes in patients with head and neck cancer

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2015, Quality of Life Research.

Treatment outcomes of concurrent chemoradiotherapy for locally advanced sinonasal squamous cell carcinoma: A single-institution study

Sang‐wook Lee, Sung-Bae Kim, Yoo-Sam Chung, 2015, Acta oto-laryngologica.

Finding and Characterizing Mammary Analogue Secretory Carcinoma of the Salivary Gland

J. Roh, Kyung-Ja Cho, Sung-Bae Kim, 2013, Korean journal of pathology.

Characteristics of metastatic brachial plexopathy in patients with breast cancer

Sung-Bae Kim, Y. Choi, K. Jung, 2019, Supportive Care in Cancer.

Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG s

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2018, European journal of cancer.

Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)

Sung-Bae Kim, S. Im, H. Kim, 2010, Breast Cancer Research and Treatment.

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

Sung-Bae Kim, J. Baselga, Bing-he Xu, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2016, Medicine.

Hepatitis B Reactivation During Adjuvant Anthracycline-Based Chemotherapy in Patients with Breast Cancer: A Single Institution's Experience

Sung-Bae Kim, S. Ahn, G. Gong, 2007, The Korean journal of internal medicine.

Brain metastases in breast cancer: prognostic factors and management

Sung Sook Lee, Sung-Bae Kim, S. Ahn, 2008, Breast Cancer Research and Treatment.

Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.

Sung Sook Lee, Kyung-Ja Cho, Sung-Bae Kim, 2007, Japanese journal of clinical oncology.

Association between tumor 18F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer

Jungsu S. Oh, Sung-Bae Kim, S. Ahn, 2022, Scientific Reports.

S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?

Sung-Bae Kim, D. Yoon, 2010, Expert review of anticancer therapy.

The role of postoperative radiotherapy after primary tumor resection in patients with de novo stage IV breast cancer

Sung-Bae Kim, S. Ahn, E. Choi, 2020, Asia-Pacific journal of clinical oncology.

Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.

Jeong Hyun Lee, J. Roh, Jae Seung Kim, 2011, International journal of radiation oncology, biology, physics.

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)

Sung-Bae Kim, Jin-Hyuk Choi, Keun-Wook Lee, 2020, BMC Cancer.

Importance of FOXP3 in prognosis and its relationship with p16 in tonsillar squamous cell carcinoma.

Kyung-Ja Cho, Sung-Bae Kim, Kwonoh Park, 2013, Anticancer research.

p16 immunohistochemistry alone is a better prognosticator in tonsil cancer than human papillomavirus in situ hybridization with or without p16 immunohistochemistry

Kyung-Ja Cho, Sang‐wook Lee, Sung-Bae Kim, 2013, Acta oto-laryngologica.

Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

Sung-Bae Kim, Yeon-Hee Park, Y. Im, 2017, European journal of cancer.

Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories

Sung-Bae Kim, Jack Junjie Chan, M. Ono, 2022, Journal of breast cancer.

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Sung-Bae Kim, J. Ajani, E. Van Cutsem, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.

Sung-Bae Kim, Yoon-Koo Kang, Jin-Hee Ahn, 2005, Breast.

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane

Sung-Bae Kim, S. Ahn, J. Park, 2004, Journal of Korean medical science.

Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: Randomized phase II multicenter trial

Sung-Bae Kim, Y. Im, S. Kang, 2014, Investigational New Drugs.

Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report

Sung-Bae Kim, S. Ahn, G. Gong, 2011, Journal of breast cancer.

Biweekly gemcitabine–paclitaxel, gemcitabine–carboplatin, or gemcitabine–cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial

Sung-Bae Kim, Bing-he Xu, Shiying Yu, 2011, Breast cancer.

Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential

Sung-Bae Kim, S. Ahn, H. Lee, 2016, Cancer Chemotherapy and Pharmacology.

Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01)

Sung-Bae Kim, Jin-Hyuk Choi, Keun-Wook Lee, 2021, Cancer research and treatment.

Prognostic factors in patients with head and neck squamous cell carcinoma with cN3 neck disease: a retrospective case-control study.

Jeong Hyun Lee, J. Roh, Sang‐wook Lee, 2014, Oral surgery, oral medicine, oral pathology and oral radiology.

Prediction of Posttreament Significant Body Weight Loss and Its Correlation with Disease-Free Survival in Patients with Oral Squamous Cell Carcinomas

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2013, Nutrition and cancer.

A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT).

Sung-Bae Kim, M. Brose, S. Sherman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ethnicity and breast cancer research

Sung-Bae Kim, C. Palmieri, R. Coombes, 2008, The Lancet.

Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex

Sung-Bae Kim, C. Sotiriou, J. Huober, 2022, Journal for ImmunoTherapy of Cancer.

A phase II trial of the pan‐HER inhibitor poziotinib, in patients with HER2‐positive metastatic breast cancer who had received at least two prior HER2‐directed regimens: results of the NOV120101‐203 trial

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2018, International journal of cancer.

Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

Sung-Bae Kim, W. Gradishar, N. Masuda, 2019, Journal of Clinical Oncology.

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.

Sung-Bae Kim, S. Goel, F. André, 2020, The Lancet. Oncology.

Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer

J. S. Kim, M. Espié, Sung-Bae Kim, 2021, Breast Cancer Research and Treatment.

Leptomeningeal Carcinomatosis in Gastric Cancer

Sung-Bae Kim, Eunkyoung Kim, H. Chang, 2004, Journal of Neuro-Oncology.

Aspirin use and head and neck cancer survival: an observational study of 11,623 person-years follow-up

J. Roh, Sung-Bae Kim, S. Choi, 2018, International Journal of Clinical Oncology.

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Sung-Bae Kim, E. Tokunaga, H. Rugo, 2022, New England Journal of Medicine.

First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody–Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer

Sung-Bae Kim, J. Berlin, F. Meric-Bernstam, 2019, Targeted Oncology.

Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients.

Sung-Bae Kim, S. Ahn, Yoon-Koo Kang, 2006, Cancer research and treatment : official journal of Korean Cancer Association.

Risk stratification system for groups with a low, intermediate, and high risk of subsequent distant metastasis and death following isolated locoregional recurrence of breast cancer

Sung-Bae Kim, S. Ahn, S. Ahn, 2019, Breast Cancer Research and Treatment.

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience

Sung-Bae Kim, J. Huh, C. Suh, 2006, The Korean Journal of Internal Medicine.

Laryngeal edema after radiotherapy in patients with squamous cell carcinomas of the larynx and hypopharynx.

Jeong Hyun Lee, J. Roh, Jae Seung Kim, 2012, Oral oncology.

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Sung-Bae Kim, W. Gradishar, M. Yamaguchi, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma

Sung-Bae Kim, J. Bernier, I. Chitapanarux, 2016, BMC Cancer.

Long-Term Survival and Tumor Recurrence in Patients with Superficial Esophageal Cancer after Complete Non-Curative Endoscopic Resection: A Single-Center Case Series

Sung-Bae Kim, G. Lee, Jong Hoon Kim, 2018, Clinical endoscopy.

Food impaction after expandable metal stent placement: experience in 1,360 patients with esophageal and upper gastrointestinal tract obstruction.

Sung-Bae Kim, Jung-Hoon Park, Ho-Young Song, 2011, Journal of vascular and interventional radiology : JVIR.

Membrane degradation of covered stents in the upper gastrointestinal tract: frequency and clinical significance.

Sung-Bae Kim, Ho-Young Song, J. Shin, 2008, Journal of vascular and interventional radiology : JVIR.

A Pilot Study for the Feasibility of F-18 FLT-PET in Locally Advanced Breast Cancer: Comparison with F-18 FDG-PET

Sung-Bae Kim, S. Ahn, Jin-Hee Ahn, 2008 .

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Sung-Bae Kim, I. Bondarenko, C. Barrios, 2021, Breast Cancer Research and Treatment.

Clinical effectiveness and safety of self-expanding metal stent placement following palliative chemotherapy in patients with advanced esophageal cancer

Sung-Bae Kim, Jung-Hoon Park, Ho-Young Song, 2019, Abdominal Radiology.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Sung-Bae Kim, A. Schneeweiss, S. Loi, 2020, The Lancet. Oncology.

Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer

Sung-Bae Kim, S. Ahn, H. Lee, 2014, BMC Cancer.

Prediction of Late Breast Cancer-Specific Mortality in Recurrence-Free Breast Cancer Survivors Treated for Five Years with Tamoxifen

Sung-Bae Kim, S. Ahn, S. Ahn, 2019, Journal of breast cancer.

Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.

Sung-Bae Kim, Yeon-Hee Park, F. André, 2020 .

A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer

Sung-Bae Kim, K. Jung, Jin-Hee Ahn, 2015, Molecular therapy. Methods & clinical development.

Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)

Sung-Bae Kim, Yeon-Hee Park, S. Im, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

A nthracycline and T axane Salvage T reatm ent of M etastatic Breast C ancer: Retrospective A naly sis of 124 Patients

Sung-Bae Kim, S. Ahn, Yoon-Koo Kang, 2009 .

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.

Sung-Bae Kim, S. Loi, R. Salgado, 2020, The Lancet. Oncology.

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2021, The Lancet.

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer

Sung-Bae Kim, Y. Im, S. Kang, 2015, Cancer research and treatment : official journal of Korean Cancer Association.

Growth inhibition and chemosensitivity of poorly differentiated human thyroid cancer cell line (NPA) transfected with p53 gene

Sung-Bae Kim, G. Gong, C. Suh, 2001, Head & neck.

Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

Sung-Bae Kim, K. Gelmon, H. Rugo, 2022, Frontiers in Oncology.

Role of surgical resection in complete responders on FDG‐PET after chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Sung-Bae Kim, G. Lee, Jong Hoon Kim, 2014, Journal of surgical oncology.

HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.

Sung-Bae Kim, Shou‐Tung Chen, J. Ahn, 2016, European journal of cancer.

Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma

Sung-Bae Kim, M. Ahn, Keun-Wook Lee, 2020, Clinical Cancer Research.

Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.

Kyung-Ja Cho, Sung-Bae Kim, G. Lee, 2020, Surgical oncology.

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Sung-Bae Kim, M. Shah, F. Lordick, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest.

Sung-Bae Kim, C. Suh, M. Ryu, 2003, Journal of Korean medical science.

Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer.

Kyung-Ja Cho, Sung-Bae Kim, Ho-Young Song, 2012, The Annals of thoracic surgery.

A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy

Sung-Bae Kim, K. Jung, Jin-Hee Ahn, 2019, Investigational New Drugs.

Can Response to Induction Chemotherapy Be a Predictive Marker for Ultimate Outcome in Hypopharyngeal Cancer?

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Radiation therapy with UFT and low dose weekly cisplatin for nasopharyngeal carcinoma.

Kyung-Ja Cho, Sang‐wook Lee, Sung-Bae Kim, 2005, Auris, nasus, larynx.

Clinical features and outcome of leptomeningeal metastasis in patients with breast cancer: a single center experience

Sung-Bae Kim, S. Ahn, S. Ahn, 2013, Cancer Chemotherapy and Pharmacology.

Translation and validation of Korean Functional Assessment of Cancer Therapy-Esophageal (FACT-E) scale with squamous cell carcinoma and chemoradiation-only patients

Kyung-Ja Cho, Sung-Bae Kim, D. Cella, 2012, Quality of Life Research.

Ibulocydine sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis via calpain-mediated Bax cleavage.

Sung-Bae Kim, E. Choi, J. Hwang, 2017, The international journal of biochemistry & cell biology.

Distant Metastases and Survival Prediction in Head and Neck Squamous Cell Carcinoma

J. Roh, Sung-Bae Kim, S. Choi, 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Predicting Successful Conservative Surgery after Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Sung-Bae Kim, S. Ahn, S. Ahn, 2018, Journal of Breast Disease.

Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study

Sung-Bae Kim, C. Suh, Jung‐Min Ahn, 2005, The Korean journal of internal medicine.

Clinical Implication of HER2 Status in Hormone Receptor-Positive Mucinous Breast Cancer

Sung-Bae Kim, S. Ahn, H. Lee, 2019, Annals of Surgical Oncology.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.

M. Espié, Sung-Bae Kim, A. Schneeweiss, 2015, The Lancet. Oncology.

In vitro Priming of Myeloma Antigen-specific Allogeneic Donor T Cells with Idiotype Pulsed Dendritic Cells

Sung-Bae Kim, L. Kwak, S. Baskar, 2003, Leukemia & lymphoma.

Quality of life on TSU‐68: Combination of docetaxel and TSU‐68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline

Sung-Bae Kim, Y. Im, S. Im, 2017, Asia-Pacific journal of clinical oncology.

Non-surgical treatment versus radical esophagectomy for clinical T1N0M0 esophageal carcinoma: a single-center experience

Kyung-Ja Cho, Sung-Bae Kim, G. Lee, 2014, Cancer Chemotherapy and Pharmacology.

Radiation-induced esophageal strictures treated with fluoroscopic balloon dilation: clinical outcomes and factors influencing recurrence in 62 patients

Young Chul Cho, Sung-Bae Kim, Jung-Hoon Park, 2018, Acta radiologica.

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Sung-Bae Kim, W. Gradishar, R. Bose, 2021, Breast Cancer Research and Treatment.

Automated Immunoassay in Breast Cancer Patients

Sung-Bae Kim, B. Son, Jung Sun Lee, 2008 .

Breast Cancer Recurrence after Smooth versus Textured Implant-Based Breast Reconstruction: A Matched Cohort Study

Sung-Bae Kim, S. Ahn, G. Gong, 2022, Plastic and reconstructive surgery.

Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data

Kyung-Ja Cho, Sung-Bae Kim, Ho-Young Song, 2012, Cancer Chemotherapy and Pharmacology.

Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial

Sung-Bae Kim, S. Im, J. Sohn, 2021, Cancer research and treatment.

Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Sung-Bae Kim, K. Jung, Jin-Hee Ahn, 2021, Cancer research and treatment.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Sung-Bae Kim, J. Baselga, A. Bardia, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Change in Estradiol Levels among Premenopausal Patients with Breast Cancer Treated Using Leuprolide Acetate 11.25 Milligrams 3-Month Depot and Tamoxifen

Sung-Bae Kim, S. Ahn, G. Gong, 2020, Journal of breast cancer.

Reply: 18F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer

Sung-Bae Kim, S. Ahn, D. Moon, 2017, The Journal of Nuclear Medicine.

High-dose chemotherapy of cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation as a consolidation for breast cancer patients with 10 or more positive lymph nodes: a 5-year follow-up results.

Sung-Bae Kim, Sang-We Kim, Jin-Hee Ahn, 2005, Cancer research and treatment : official journal of Korean Cancer Association.

T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.

Sung-Bae Kim, J. Lunceford, M. Ayers, 2022, Future oncology.

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

P. Fasching, Sung-Bae Kim, W. Gradishar, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01)

Sung-Bae Kim, Jin-Hyuk Choi, Keun-Wook Lee, 2021, The Korean journal of internal medicine.

T ransplantation for M etastatic Breast C ancer Patients: A 6- Y ear Follow -U p Result

Sung-Bae Kim, Sang-We Kim, Jin-Hee Ahn, 2009 .

High-dose chemotherapy of cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation for metastatic breast cancer patients: a 6-year follow-up result.

Sung-Bae Kim, Sang-We Kim, Jin-Hee Ahn, 2005, Cancer research and treatment : official journal of Korean Cancer Association.

Clinical evaluation of incadronate in korean patients with malignancy-associated hypercalcemia: An open-label, multicenter study.

Sung-Bae Kim, Joon-Oh Park, Keunchil Park, 2007, Current therapeutic research, clinical and experimental.

Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients

Sung-Bae Kim, Y. Im, L. Cartee, 2013, Clinical pharmacology in drug development.

Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.

Sung-Bae Kim, M. Piccart, J. Baselga, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)

Sung-Bae Kim, Yeon-Hee Park, Y. Im, 2019, British Journal of Cancer.

Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer.

Sung-Bae Kim, H. Iwata, Bing-he Xu, 2019, Future oncology.

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy

Sung-Bae Kim, S. Ahn, K. Jung, 2012, Cancer Chemotherapy and Pharmacology.

Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.

Sung-Bae Kim, Sang-We Kim, C. Suh, 1998, Journal of Korean medical science.

Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma.

Kyung-Ja Cho, Sang‐wook Lee, Sung-Bae Kim, 2005, International journal of radiation oncology, biology, physics.

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

Sung-Bae Kim, H. Iwata, Byeong‐Woo Park, 2017, The New England journal of medicine.

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy

Sung-Bae Kim, J. Jeong, 2022, Breast.

Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy

Sung-Bae Kim, J. Reeves, C. Shimizu, 2022, JAMA oncology.

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Sung-Bae Kim, R. Greil, S. Kuemmel, 2021, Clinical Cancer Research.

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

Min Hwan Kim, Sung-Bae Kim, Chiun-Sheng Huang, 2022, The New England journal of medicine.

Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling

Taehoon Lee, Young-Pil Kim, Sei-Hyun Ahn, 2014, Breast Cancer Research.

Correction to: ECM1 regulates cell proliferation and trastuzumab resistance through activation of EGF-signaling

Sung-Bae Kim, D. Noh, S. Ahn, 2019, Breast Cancer Research.

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2021 .

Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancer.

Kyung-Ja Cho, Sung-Bae Kim, Ho-Young Song, 2015, International journal of radiation oncology, biology, physics.

Collection of peripheral blood progenitor cells: analysis of factors predicting the yields.

Sung-Bae Kim, C. Suh, M. Ryu, 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer

Sung-Bae Kim, Yeon-Hee Park, S. Im, 2008, Breast Cancer Research and Treatment.

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies

Sung-Bae Kim, J. H. Park, Jin-Hee Ahn, 2018, ESMO Open.

Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.

Sung-Bae Kim, S. Ahn, G. Gong, 2006, Human pathology.

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Sung-Bae Kim, C. Sotiriou, L. Pusztai, 2021, Clinical Cancer Research.

A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01).

Sung-Bae Kim, M. Ahn, Keunchil Park, 2012, European journal of cancer.

Prognostic factors and oncologic outcomes of 56 salivary duct carcinoma patients in a single institution: high rate of systemic failure warrants targeted therapy.

J. Roh, Kyung-Ja Cho, Sung-Bae Kim, 2014, Oral oncology.

Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine.

Sung-Bae Kim, S. Ahn, G. Gong, 2011, Japanese journal of clinical oncology.

Raloxifene induces autophagy-dependent cell death in breast cancer cells via the activation of AMP-activated protein kinase.

Dong Eun Kim, Sung-Bae Kim, E. Choi, 2015, Molecules and cells.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Sung-Bae Kim, E. Tokunaga, H. Iwata, 2019, The New England journal of medicine.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

Sung-Bae Kim, S. Paik, J. Chiu, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) versus treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

Sung-Bae Kim, H. Wildiers, I. Krop, 2016 .

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Sung-Bae Kim, H. Wildiers, P. LoRusso, 2014, The Lancet. Oncology.

Management of ErbB2-positive Breast Cancer: Insights from Preclinical and Clinical Studies with Lapatinib

Sung-Bae Kim, B. Gril, J. Kurebayashi, 2010, Japanese journal of clinical oncology.

Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 in patients with metastatic breast cancer: phase II randomized, placebo-controlled study

Sung-Bae Kim, L. Chow, Chiun-Sheng Huang, 2020, Journal for ImmunoTherapy of Cancer.

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sung-Bae Kim, S. Loi, Chiun-Sheng Huang, 2022, The Lancet.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

M. Espié, Sung-Bae Kim, J. Baselga, 2017, The Lancet. Oncology.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer

Sung-Bae Kim, S. Ahn, H. Lee, 2015, Tumor Biology.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Sung-Bae Kim, A. Dechaphunkul, É. Remenár, 2017, The Lancet. Oncology.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Sung-Bae Kim, Y. Doki, M. Okada, 2019, The Lancet. Oncology.

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations

Sung-Bae Kim, K. Harrington, M. Ahn, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma

J. Roh, Sung-Bae Kim, S. Choi, 2017, The Laryngoscope.

Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas

J. Roh, Kyung-Ja Cho, Sang‐wook Lee, 2014, Journal of surgical oncology.

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial

Sung-Bae Kim, Choung-Soo Kim, S. Kwon, 2011, Journal of Translational Medicine.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

Sung-Bae Kim, J. Lunceford, M. Shah, 2019, JAMA oncology.

Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial

Sung-Bae Kim, Choung-Soo Kim, S. Kwon, 2014, Cellular and Molecular Immunology.

Abstract P5-19-07: Randomized Phase II trial of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients with HER2-positive breast cancer with progressive brain metastases after trastuzumab and/or lapatinib-based therapy: LUX-Breast 3

M. Espié, Sung-Bae Kim, A. Schneeweiss, 2015 .

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Sung-Bae Kim, M. Buyse, M. Gnant, 2017, The Lancet. Oncology.

Retrievable covered nitinol stents: experiences in 108 patients with malignant esophageal strictures.

Ho-Young Song, Tae-Seok Seo, Deok Hee Lee, 2002, Journal of vascular and interventional radiology : JVIR.

Management of Tracheomediastinal Fistula Using a Self-Expanding Metallic Tracheal Stent

Sung-Bae Kim, Ho-Young Song, J. Shin, 2009, CardioVascular and Interventional Radiology.

Evaluation of the incidence of esophageal complications associated with balloon dilation and their management in patients with malignant esophageal strictures.

Sung-Bae Kim, Jung-Hoon Park, Ho-Young Song, 2012, AJR. American journal of roentgenology.

Covered metallic stent placement in the management of cervical esophageal strictures.

Sung-Bae Kim, Ho-Young Song, J. Shin, 2007, Journal of vascular and interventional radiology : JVIR.

Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]

Sung-Bae Kim, S. Ahn, Deokhoon Kim, 2020, AntiCancer Research.

Circulating Tumor DNA and Biomarker Analyses From the LOTUS Randomized Trial of First-Line Ipatasertib and Paclitaxel for Metastatic Triple-Negative Breast Cancer.

Sung-Bae Kim, D. Lipson, M. Wongchenko, 2020, JCO precision oncology.

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Sung-Bae Kim, C. Geyer, J. Bonneterre, 2013, European journal of cancer.

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Sung-Bae Kim, A. Schneeweiss, J. Baselga, 2013, The Lancet. Oncology.

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12

Sung-Bae Kim, M. Ahn, Keun-Wook Lee, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.

Sung-Bae Kim, H. Wildiers, P. LoRusso, 2017, The Lancet. Oncology.

Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)

Sung-Bae Kim, S. Kang, Jin-Hee Ahn, 2021, Therapeutic advances in medical oncology.

Temporary stent placement with concurrent chemoradiation therapy in patients with unresectable oesophageal carcinoma: is there an optimal time for stent removal?

Sung-Bae Kim, Jung-Hoon Park, Ho-Young Song, 2013, European Radiology.

Impact of Triple-Negative Breast Cancer Phenotype on Prognosis in Patients with Stage I Breast Cancer

Sung-Bae Kim, S. Ahn, G. Gong, 2012, Journal of breast cancer.

No Association of Positive Superficial and/or Deep Margins with Local Recurrence in Invasive Breast Cancer Treated with Breast-Conserving Surgery

Sung-Bae Kim, S. Ahn, S. Ahn, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Plasma Proteome Signature to Predict the Outcome of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Sung-Bae Kim, S. Ahn, H. Lee, 2021, Cancers.

Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Sung-Bae Kim, Seung‐Mo Hong, Jong Hoon Kim, 2021, Cancer research and treatment.

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

Sung-Bae Kim, W. Gradishar, R. Bose, 2021, The oncologist.

Analysis of clinical outcomes and prognostic factors in patients treated with definitive chemoradiotherapy for oesophageal squamous cell carcinoma

Sung-Bae Kim, G. Lee, Jong Hoon Kim, 2021, Cancer medicine.

Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients

Sung-Bae Kim, S. Ahn, H. Lee, 2020, Scientific Reports.

Correction to: Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12

Sung-Bae Kim, M. Ahn, I. Hwang, 2020, Journal of Cancer Research and Clinical Oncology.

Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18–12

Sung-Bae Kim, M. Ahn, I. Hwang, 2020, Journal of Cancer Research and Clinical Oncology.

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2019, The Lancet. Oncology.

A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESOPRESSO)

Kyung-Ja Cho, Sung-Bae Kim, G. Lee, 2019, AntiCancer Research.

Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study

Sung-Bae Kim, C. Shimizu, H. Mukai, 2019, Journal of global oncology.

Prognostic value of circulating biomarker score in advanced-stage head and neck squamous cell carcinoma.

J. Roh, Sung-Bae Kim, S. Choi, 2018, European journal of cancer.

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2022, Cancer research and treatment.

Comparison of Microvessel Density Before and after Peripheral Blood Stem Cell Transplantation in Multiple Myeloma Patients and Its Clinical Implications: Multicenter Trial

Sung-Bae Kim, Q. Park, M. Ahn, 2002, International journal of hematology.

Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study.

Sung-Bae Kim, S. Ahn, G. Gong, 2019, The Lancet. Oncology.

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

Sung-Bae Kim, A. Schneeweiss, S. Swain, 2019, Journal of Clinical Oncology.

A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.

Sung-Bae Kim, S. Loi, A. Bardia, 2020 .

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

Sung-Bae Kim, M. Schlumberger, S. Sherman, 2016, The Journal of clinical endocrinology and metabolism.

F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma.

Jeong Hyun Lee, Jae Seung Kim, Sang‐wook Lee, 2007, Oral Oncology.

Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.

Ga Young Yoon, Sung-Bae Kim, H. Kim, 2020, Clinical breast cancer.

18F‐fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: A retrospective cohort study

Sung-Bae Kim, S. Ahn, G. Gong, 2013, Journal of surgical oncology.

Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES

Sung-Bae Kim, Y. Im, S. Im, 2021, Breast Cancer Research and Treatment.

A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor–Rich Postmenopausal Breast Cancer

Sung-Bae Kim, S. Ahn, G. Gong, 2017, The Journal of Nuclear Medicine.

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers

Derek Y. Chiang, Angad P. Singh, Sung-Bae Kim, 2018, npj Breast Cancer.

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.

Sung-Bae Kim, L. Carey, R. Bose, 2016, JAMA oncology.

A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).

Sung-Bae Kim, A. Bardia, Chiun-Sheng Huang, 2015 .

Metastatic Tumors to the Breast from Extramammary Malignancies

Sung-Bae Kim, S. Ahn, G. Gong, 2010 .

Clinical Characteristics and Prognostic Factors of Adenoid Cystic Carcinoma of the Head and Neck

Kyung-Ja Cho, Sang‐wook Lee, Sung-Bae Kim, 2013, The Laryngoscope.

Can concurrent chemoradiotherapy replace surgery and postoperative radiation for locally advanced stage III/IV tonsillar squamous cell carcinoma?

Young Seok Kim, J. Roh, Sang‐wook Lee, 2013, Anticancer research.

Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2016, Journal of Cancer Research and Clinical Oncology.

Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer

Sung-Bae Kim, H. Lee, G. Gong, 2023, Therapeutic advances in medical oncology.

FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment

Sung-Bae Kim, H. Lee, G. Gong, 2018, Journal of breast cancer.

Pretreatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2016, Cancer.

Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: The Korean Cancer Study Group BR 07-01

Sung-Bae Kim, D. Noh, J. Ahn, 2012, Breast Cancer Research and Treatment.

Low‐dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses

Sung-Bae Kim, Kihyun Kim, C. Suh, 2004, Transfusion.

A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.

Sung-Bae Kim, K. Yonemori, M. Beeram, 2021 .

A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746).

Sung-Bae Kim, Yeon-Hee Park, Y. Im, 2019, Journal of Clinical Oncology.

Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

P. Fasching, Sung-Bae Kim, M. Piccart, 2021 .

Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer – Proceedings from breast cancer expert group meeting

Sung-Bae Kim, S. Franco, C. Villarreal-Garza, 2021, BMC Proceedings.

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

Sung-Bae Kim, J. Baselga, E. Tokunaga, 2021 .

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

Eileen Holmes, Patrick Flamen, Camilo Garcia, 2013, The Journal of Nuclear Medicine.

Experience of Ovarian Function Suppression Therapy: Endocrine Response Preand Perimenopausal Korean Breast Cancer Patients in the Adjuvant Setting

Sung-Bae Kim, B. Son, Jin-Hee Ahn, 2007 .

Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy.

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Clinicopathologic significance of the K‐ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases

J S Lee, Sung-Bae Kim, Sang-We Kim, 1995, Cancer.

Prediction of outcomes for patients with brain parenchymal metastases from breast cancer (BC): a new BC-specific prognostic model and a nomogram.

Sung-Bae Kim, J. Ahn, Yeon-Hee Park, 2012, Neuro-oncology.

Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.

Myung Ah Lee, Sung-Bae Kim, Yeon-Hee Park, 2005, Oncology reports.

Efficacy of assessing circulating cell-free DNA using a simple fluorescence assay in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a prospective observational study

Sung-Bae Kim, G. Gong, K. Jung, 2017, Oncotarget.

Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.

Sung-Bae Kim, M. Shah, F. Lordick, 2019, Journal of Clinical Oncology.

Comparison of temporary and permanent stent placement with concurrent radiation therapy in patients with esophageal carcinoma.

Ho-Young Song, Ji Hoon Shin, Weechang Kang, 2005, Journal of vascular and interventional radiology : JVIR.

Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma

Sung-Bae Kim, J. Bernier, I. Chitapanarux, 2016, BMC Cancer.

Evaluation of 18F-FDG PET/CT and CT/MRI with Histopathologic Correlation in Patients Undergoing Salvage Surgery for Head and Neck Squamous Cell Carcinoma

Jeong Hyun Lee, J. Roh, Jae Seung Kim, 2011, Annals of Surgical Oncology.

An Introduction to a Head and Neck Cancer-Specific Frailty Index and Its Clinical Implications in Elderly Patients: A Prospective Observational Study Focusing on Respiratory and Swallowing Functions.

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2016, The oncologist.

Alternative Therapy and Abnormal Liver Function During Adjuvant Chemotherapy in Breast Cancer Patients

Sung-Bae Kim, Yoon-Koo Kang, Jin-Hee Ahn, 2004, Journal of Korean medical science.

Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).

Sung-Bae Kim, Sin-Ho Jung, M. Ahn, 2016, Radiotherapy and Oncology.

LOTUS: A randomized, phase II, multicenter, placebo-controlled study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).

Sung-Bae Kim, V. Valero, A. Tan, 2015 .

Abstract OT1-1-16: A randomized, multicenter, phase II study of ipatasertib (Ipat, GDC-0068), an inhibitor of Akt, in combination with paclitaxel (Pac) as front-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC)

Sung-Bae Kim, V. Valero, T. Traina, 2015 .

Prevalence and clinical significance of cancer cachexia based on time from treatment in advanced‐stage head and neck squamous cell carcinoma

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2017, Head & neck.

Clinical features and course of brain metastases in triple-negative breast cancer: comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea

Sung-Bae Kim, S. Ahn, S. Ahn, 2011, Breast Cancer Research and Treatment.

Clinical value of cyclooxygenase-2 expression in human breast carcinoma.

Sung-Bae Kim, S. Ahn, M. Ahn, 2004, Cancer research and treatment : official journal of Korean Cancer Association.

Prognostic value of neutrophil-to-lymphocyte ratio in older patients with head and neck cancer.

J. Roh, Sung-Bae Kim, S. Choi, 2020, Journal of geriatric oncology.

Palliative treatment of unresectable esophagogastric junction tumors: balloon dilation combined with chemotherapy and/or radiation therapy and metallic stent placement.

Sung-Bae Kim, Ho-Young Song, J. Shin, 2008, Journal of vascular and interventional radiology : JVIR.

Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.

Sung-Bae Kim, S. Franco, C. Villarreal-Garza, 2020, Chinese clinical oncology.

Knowledge, attitudes, and behaviors toward fertility preservation in patients with breast cancer: A cross-sectional survey of physicians

Sung-Bae Kim, T. Vidaurre, Yeon-Hee Park, 2023, Frontiers in Oncology.

MRI-based 3D-printed surgical guides for breast cancer patients who received neoadjuvant chemotherapy

Sung-Bae Kim, G. Kim, J. Seo, 2019, Scientific Reports.

Prognostic value of body composition on recurrence and survival of advanced-stage head and neck cancer.

J. Roh, Jae Seung Kim, Sung-Bae Kim, 2019, European journal of cancer.

Chemotherapy-induced amenorrhea, menopause-specific quality of life, and endocrine profiles in premenopausal women with breast cancer who received adjuvant anthracycline-based chemotherapy: a prospective cohort study

Sung-Bae Kim, H. Kim, K. Jung, 2013, Cancer Chemotherapy and Pharmacology.

Recurrence Outcomes After Nipple-Sparing Mastectomy and Immediate Breast Reconstruction in Patients with Pure Ductal Carcinoma In Situ

Sung-Bae Kim, S. Ahn, B. Son, 2020, Annals of Surgical Oncology.

Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)

Sung-Bae Kim, Y. Doki, M. Okada, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Correlation between the Her-2/neu Status as Determined by Immunohistochemical Analysis and the Serum Her-2/neu Concentration as Determined by the Use of ADVIA Cencaur® Automated Immunoassay in Breast Cancer Patients

Sung-Bae Kim, S. Ahn, B. Son, 2008 .

RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

Sung-Bae Kim, J. Ajani, C. Borg, 2021 .

Data on distant metastasis and survival after locoregional recurrence following nipple-sparing mastectomy and immediate breast reconstruction

Sung-Bae Kim, S. Ahn, G. Gong, 2021, Data in brief.

Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study

Sung-Bae Kim, Yeon-Hee Park, Y. Im, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results

Sung-Bae Kim, Yeon-Hee Park, E. Cho, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

Sung-Bae Kim, E. Tokunaga, Yeon-Hee Park, 2021 .

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Sung-Bae Kim, W. Gradishar, H. Wildiers, 2021, Clinical Cancer Research.

IPATunity130: A pivotal randomized phase III trial evaluating ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered advanced triple-negative (TN) or hormone receptor-positive HER2-negative (HR+/HER2–) breast cancer (BC).

Sung-Bae Kim, J. Baselga, C. Barrios, 2018 .

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers

Sung-Bae Kim, S. Ahn, H. Lee, 2015, PloS one.

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Sung-Bae Kim, Yeon-Hee Park, F. André, 2023, The Lancet.

CT Findings From Interstitial Lung Diseases in Patients With Metastatic Breast Cancer Treated With Fam-Trastuzumab Deruxtecan: A Single Institutional Experience

Sung-Bae Kim, K. Jung, Jin-Hee Ahn, 2021, Journal of breast cancer.

Phase 1b/2 study of GX-I7 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.

Sung-Bae Kim, Y. Im, Se-Hwan Yang, 2022, Journal of Clinical Oncology.

Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.

Sung-Bae Kim, H. Iwata, G. Curigliano, 2022, Journal of Clinical Oncology.

Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03

Sung-Bae Kim, H. Iwata, Yeon-Hee Park, 2022, Cancer Research.

Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)

Sung-Bae Kim, E. Tokunaga, H. Iwata, 2020 .

Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02

Sung-Bae Kim, Yeon-Hee Park, F. André, 2023, Cancer Research.

PS2-1 Trastuzumab deruxtecan vs T-DM1 in HER2+ mBC in Asian subgroup: Results of the randomized phase 3 study DESTINY-Breast03

Sung-Bae Kim, Chiun-Sheng Huang, H. Iwata, 2022, Annals of Oncology.

Abstract PD8-01: Phase 3 SOPHIA study of margetuximab (M) + chemotherapy (CTX) vs trastuzumab (T) + CTX in patients (pts) with HER2+ metastatic breast cancer (MBC) after prior anti-HER2 therapies: Final overall survival (OS) analysis

P. Fasching, Sung-Bae Kim, W. Gradishar, 2022, Cancer Research.

Abstract PS10-12: Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC)

Sung-Bae Kim, W. Gradishar, E. Rock, 2021 .

Is asymptomatic surveillance beneficial after standard treatment? A 10‐year survival analysis of recurrent BC patients by detection method of recurrence

Sung-Bae Kim, S. Ahn, H. Lee, 2020, The breast journal.

Use of 18F-FDG PET for Primary Treatment Strategy in Patients with Squamous Cell Carcinoma of the Oropharynx

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2007, Journal of Nuclear Medicine.

Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study

Sung-Bae Kim, S. Ahn, B. Son, 2018, Journal of breast cancer.

Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer

Sung-Bae Kim, E. Choi, Su Ssan Kim, 2021, Breast Cancer Research and Treatment.

Risk factors for competing non-cancer mortality after definitive treatment for advanced-stage head and neck cancer.

J. Roh, Sung-Bae Kim, S. Choi, 2018, Oral diseases.

Early assessment of tumor response to JAC106, an anti-tubulin agent, by 3′-deoxy-3′-[18F]fluorothymidine in preclinical tumor models

Sung-Bae Kim, S. Oh, Song-Kyu Park, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.

Sung-Bae Kim, K. Jung, Jin-Hee Ahn, 2020, European journal of cancer.

RNA Sequencing for Elucidating an Intronic Variant of Uncertain Significance (SDHD c.314+3A>T) in Splicing Site Consensus Sequences

Sung-Bae Kim, Woochang Lee, S. Chun, 2022, Annals of laboratory medicine.

Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).

Sung-Bae Kim, S. Loi, D. Miles, 2019, Journal of Clinical Oncology.

Intramedullary spinal cord metastases: a single-institution experience

Sung-Bae Kim, Jin-Hee Ahn, S. Sym, 2007, Journal of Neuro-Oncology.

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01)

Sung-Bae Kim, Jin-Hyuk Choi, B. Keam, 2020, BMC Cancer.

Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients

Sung-Bae Kim, S. Ahn, H. Lee, 2014, Breast Cancer Research and Treatment.

Role of Esophagectomy after Chemoradiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma: A Comparative Analysis Stratified by Clinical Response to Chemoradiation Therapy

Sung-Bae Kim, Jong Hoon Kim, H. Song, 2021, Cancer research and treatment.

Impact of Immunohistochemistry-Based Molecular Subtype on Chemosensitivity and Survival in Patients with Breast Cancer Following Neoadjuvant Chemotherapy

Hee Jung Shin, Jin-Hee Ahn, Kyung Hae Jung, 2012, Journal of breast cancer.

Impact of sequential lines of palliative chemotherapy in patients with recurrent/metastatic esophageal squamous cell carcinoma: A retrospective analysis of 107 patients at a single center

Sung-Bae Kim, Jong Hoon Kim, H. Song, 2020, Asia-Pacific journal of clinical oncology.

First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors.

Sung-Bae Kim, C. Ock, K. Bae, 2021 .

Early evaluation of the response to radiotherapy of patients with squamous cell carcinoma of the head and neck using 18FDG-PET.

Jin-Sook Ryu, Dae Hyuk Moon, Bong-Jae Lee, 2005, Oral oncology.

Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.

Sung-Bae Kim, Yeon-Hee Park, S. Im, 2017 .

Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma

Sung-Bae Kim, C. Borg, B. Buecher, 2019, Annals of Oncology.

Abstract A070: A phase 1/2a, open-label, dose-escalation study of EC-18 in patients with metastatic breast cancer for the prevention of chemotherapy-induced neutropenia

Sung-Bae Kim, Myung-Hwan Kim, 2019 .

Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers

Derek Y. Chiang, Angad P. Singh, Sung-Bae Kim, 2018, npj Breast Cancer.

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.

Sung-Bae Kim, H. Lee, G. Gong, 2022, European journal of cancer.

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Sung-Bae Kim, M. Shah, B. Robinson, 2017, Thyroid : official journal of the American Thyroid Association.

Response to letter to the editor re: Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy.

Sung-Bae Kim, Sora Kang, 2022, European journal of cancer.

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer

Sung-Bae Kim, S. Ahn, S. Ahn, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study

Sung-Bae Kim, Tae Won Kim, Sang-We Kim, 2021, Cancer Medicine.

Prognostic implications of human epidermal growth factor receptor 2 change after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-zero and human epidermal growth factor receptor 2-low breast cancer

Sung-Bae Kim, H. Lee, G. Gong, 2023, European Journal of Cancer.

Prognostic value of tumour infiltrating lymphocytes (TILs) in patients with early-stage triple negative breast cancers (TNBC) in the absence of chemotherapy

Sung-Bae Kim, S. Loi, A. Vincent-Salomon, 2019, Annals of Oncology.

Prognostic significance of lymph node ratio after neoadjuvant chemoradiation therapy for esophageal squamous cell carcinoma

Sung-Bae Kim, Jong Hoon Kim, Sook Ryun Park, 2020, Radiation oncology journal.

The Clinical Characteristics and Outcome of Breast Cancer Patients Older than 70 Years.

Sung-Bae Kim, S. Ahn, S. Ahn, 2007 .

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Sung-Bae Kim, M. Buyse, N. Robert, 2019, Breast Cancer Research.

The Usefulness of Periareolar Zigzag Incision in Breast Conserving-Surgery in Breast Cancer Patients: Experience in a Single Institution

Sung-Bae Kim, S. Ahn, B. Son, 2020 .

P30 Tissue microarray-based studies of patients with lymph node-negative breast carcinoma show that HER-2/neu overexpression is an important predictive marker of poor prognosis

M. Kim, S. Lee, Sung-Bae Kim, 2007 .

Docetaxel‐based adjuvant therapy for breast cancer patients in Asia‐Pacific region: Results from 5 years follow‐up on Asia‐Pacific Breast Initiative‐I

Sung-Bae Kim, A. Sayeed, A. Villalon, 2016, Asia-Pacific journal of clinical oncology.

Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment

J. Roh, Kyung-Ja Cho, Sang‐wook Lee, 2015, Journal of Cancer Research and Clinical Oncology.

The Feasibility of 18F-Fluorothymidine PET for Prediction of Tumor Response after Induction Chemotherapy Followed by Chemoradiotherapy with S-1/Oxaliplatin in Patients with Resectable Esophageal Cancer

Sung-Bae Kim, Ho-Young Song, G. Lee, 2012, Nuclear Medicine and Molecular Imaging.

The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma.

Sung-Bae Kim, Eunkyoung Kim, C. Suh, 2003, Yonsei medical journal.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer.

Sung-Bae Kim, Chiun-Sheng Huang, H. Rugo, 2022, Future oncology.

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Sung-Bae Kim, Yeon-Hee Park, G. Jerusalem, 2022, Cancer discovery.

Clinical usefulness of the hematopoietic progenitor cell counts in predicting the optimal timing of peripheral blood stem cell harvest.

Sung-Bae Kim, C. Suh, M. Ryu, 2003, Journal of Korean medical science.

NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer

Sung-Bae Kim, M. Cheang, R. Coombes, 2014, Breast Cancer Research and Treatment.

Abstract PD9-05: Stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients

Sung-Bae Kim, S. Leung, S. Loi, 2023, Cancer Research.

Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01)

Sung-Bae Kim, Jin-Hyuk Choi, Keun-Wook Lee, 2023, Cancers.

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.

Sung-Bae Kim, S. Loi, V. Karantza, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

Sung-Bae Kim, M. Buyse, N. Robert, 2019, Breast Cancer Research.

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

Sung-Bae Kim, H. Wildiers, I. Krop, 2016, International journal of cancer.

Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).

Sung-Bae Kim, Y. Im, N. Le, 2020 .

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.

Sung-Bae Kim, S. Loi, A. Vincent-Salomon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2015, The oncologist.

Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine.

Sung-Bae Kim, C. Swanton, S. Johnston, 2016 .

BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Sung-Bae Kim, A. Dechaphunkul, É. Remenár, 2016 .

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2022, Journal of Clinical Oncology.

Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia.

Sung-Bae Kim, L. Chow, Bing-he Xu, 2019, Future oncology.

Abstract PS9-02: Neratinib + capecitabine sustains health-related quality of life (HRQoL) while improving progression-free survival (PFS) in patients with HER2+ metastatic breast cancer and ≥2 prior HER2-directed regimens

Sung-Bae Kim, W. Gradishar, R. Bose, 2021 .

Evaluation of the willingness‐to‐pay for cancer treatment in Korean metastatic breast cancer patients: A multicenter, cross‐sectional study

Sung-Bae Kim, H. Chung, D. Oh, 2012, Asia-Pacific journal of clinical oncology.

Overall survival (OS) update of the double-blind placebo (PBO)-controlled randomized phase 2 LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for locally advanced/metastatic triple-negative breast cancer (mTNBC).

M. Espié, Sung-Bae Kim, J. Baselga, 2018 .

Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel

Sung-Bae Kim, S. Loi, Yeon-Hee Park, 2023, Drug Safety.

Characteristics of metastatic brachial plexopathy in patients with breast cancer

Sung-Bae Kim, K. Jung, S. Seo, 2019, Supportive Care in Cancer.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Raloxifene induces autophagy-dependent cell death in breast cancer cells via the activation of AMP-activated protein kinase.

Dong Eun Kim, Sung-Bae Kim, E. Choi, 2015, Molecules and cells.

S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer?

Sung-Bae Kim, D. Yoon, 2010, Expert Review of Anticancer Therapy.

Sung-Bae Kim, E. Perez, R. Gelber, 2014, The Lancet. Oncology.

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Sung-Bae Kim, S. Loi, Chiun-Sheng Huang, 2022, The Lancet.

A phase 2 multicenter study of docetaxel‐PM and trastuzumab‐pkrb combination therapy in recurrent or metastatic salivary gland carcinomas

Sung-Bae Kim, M. Ahn, Keun-Wook Lee, 2023, Cancer.

Can Response to Induction Chemotherapy Be a Predictive Marker for Ultimate Outcome in Hypopharyngeal Cancer?

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2012, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

Hypopharyngeal Cancer? Can Response to Induction Chemotherapy Be a Predictive Marker for Ultimate Outcome in

J. Roh, Sang‐wook Lee, Sung-Bae Kim, 2012 .

21‐gene expression assay and clinical outcomes of premenopausal patients with hormone receptor‐positive breast cancer

Sung-Bae Kim, G. Gong, K. Jung, 2023, International journal of cancer.

A Study on the Improvement of Blood Donor Health Questionnaire

Sung-Bae Kim, Sukil Kim, S. Kwon, 2009 .

A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.

Sung-Bae Kim, Chiun-Sheng Huang, H. Rugo, 2022, Journal of Clinical Oncology.

Abstract PR08: Preliminary results from a phase 2 trial of tipifarnib in squamous cell carcinomas (SCCs) with HRAS mutations

Sung-Bae Kim, K. Harrington, M. Ahn, 2019, Clinical Trials.

Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B

Sung-Bae Kim, C. Denkert, K. Gelmon, 2021 .

A phase Ia/Ib study of novel anti‐ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer

Sung-Bae Kim, M. Ahn, B. Keam, 2023, International journal of cancer.